Literature DB >> 26221861

Mucoepidermoid Carcinoma in Children: A Single Institutional Experience.

Piti Techavichit1,2, M John Hicks3, Dolores H López-Terrada3, Norma M Quintanilla3, R Paul Guillerman4, Stephen F Sarabia3, Hadi Sayeed3, Jed G Nuchtern5, Arnold C Paulino6,7, Jodi A Muscal1, M Fatih Okcu1, Murali Chintagumpala1.   

Abstract

PURPOSE AND
OBJECTIVE: To determine the clinicopathologic and molecular features and outcome of children with mucoepidermoid carcinoma (MEC).
METHODS: A retrospective analysis of clinical and histopathologic findings was performed in patients with MEC diagnosed at Texas Children's Cancer Center between 2000 and 2014.
RESULTS: Ten female and four male patients with median age 12 years (range 7-19 years) were included in the study. Tumors involved major salivary glands, minor salivary glands of the palate, and the tracheobronchial tree. Nine of 11 patients with salivary MEC underwent more than one surgical resection at the time of initial diagnosis to achieve a gross total resection. Three patients with tracheobronchial tumors underwent pulmonary lobectomy. Three patients received postoperative radiation therapy. No patient was treated with chemotherapy. Histopathologic grades were classified as low (n = 2), intermediate (n = 9), and high (n = 3). All 12 patients with tumor tissue available for testing were positive for MECT1/MAML2 fusion transcripts. There were no deaths, metastases, or recurrences in this series, with a median follow-up of 24 months (range 5-96 months).
CONCLUSIONS: Low to intermediate histopathologic grade MECs are more common than high grade MEC in children. In contrast to adults, MECT1/MAML2 fusion transcripts occur with a frequency of 100% in our pediatric MEC series. Complete excision is the treatment of choice and is associated with excellent outcome. The role of radiotherapy is unclear, but may be indicated in patients with high grade tumors with positive surgical margins.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  MECT1-MAML2 fusion; children; mucoepidermoid carcinoma

Mesh:

Substances:

Year:  2015        PMID: 26221861     DOI: 10.1002/pbc.25681

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  5 in total

1.  Locally Advanced Stage High-Grade Mucoepidermoid Carcinoma of Salivary Gland in a 9-Year-Old Girl: The Controversy of Adjuvant Therapy.

Authors:  Olga Micol Martínez; Elena Daghoum Dorado; María Dolores Amorós García; María Isabel Oviedo Ramírez; Isabel de la Fuente Muñoz; Jose Luis Fuster Soler
Journal:  Rare Tumors       Date:  2016-10-06

2.  Low-Grade Mucoepidermoid Carcinoma of the Lacrimal Gland in a Teenaged Patient.

Authors:  Ozgun Melike Gedar Totuk; Mustafa Kemal Demir; Ozlem Yapicier; Mert Mestanoglu
Journal:  Case Rep Ophthalmol Med       Date:  2017-11-28

Review 3.  Advance oropharyngeal mucoepidermoid carcinoma in a 9-year-old boy: A case report and review of literature.

Authors:  Abdulrazak Ajiya; Iliyasu Yunusa Shuaibu; Mansur Adamu Yahuza
Journal:  Afr J Paediatr Surg       Date:  2022 Apr-Jun

4.  Prognostic impact of CRTC1/3-MAML2 fusions in salivary gland mucoepidermoid carcinoma: A multiinstitutional retrospective study.

Authors:  Yoshihide Okumura; Satsuki Nakano; Takayuki Murase; Kaori Ueda; Daisuke Kawakita; Toshitaka Nagao; Kimihide Kusafuka; Makoto Urano; Hidetaka Yamamoto; Satoshi Kano; Kiyoaki Tsukahara; Kenji Okami; Toru Nagao; Nobuhiro Hanai; Hiroshi Iwai; Ryo Kawata; Yuichiro Tada; Ken-Ichi Nibu; Hiroshi Inagaki
Journal:  Cancer Sci       Date:  2020-09-14       Impact factor: 6.716

5.  Mucoepidermoid carcinoma of the salivary glands revisited with special reference to histologic grading and CRTC1/3-MAML2 genotyping.

Authors:  André Fehr; Sarah Werenicz; Pietro Trocchi; Markus Falk; Reinhard E Friedrich; Angelika Stammler; Andreas Stang; Florian Oesterling; Laura Khil; Göran Stenman; Werner Böcker; Katharina Tiemann; Thomas Löning
Journal:  Virchows Arch       Date:  2021-07-07       Impact factor: 4.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.